Lake Street Capital started coverage on shares of BioTime (NYSEAMERICAN:BTX) in a research note issued to investors on Friday, February 2nd, MarketBeat Ratings reports. The firm issued a buy rating and a $8.00 price objective on the biotechnology company’s stock.
A number of other equities research analysts have also commented on BTX. Zacks Investment Research upgraded BioTime from a hold rating to a buy rating and set a $2.75 target price on the stock in a research report on Wednesday, November 15th. BidaskClub lowered BioTime from a sell rating to a strong sell rating in a research report on Wednesday, October 18th. Three investment analysts have rated the stock with a sell rating and three have given a buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of $5.81.
BioTime (NYSEAMERICAN:BTX) opened at $2.60 on Friday. BioTime has a fifty-two week low of $2.10 and a fifty-two week high of $3.62. The stock has a market cap of $323.63, a PE ratio of 6.05 and a beta of 1.95.
TRADEMARK VIOLATION WARNING: “BioTime (NYSEAMERICAN:BTX) Now Covered by Analysts at Lake Street Capital” was published by Week Herald and is owned by of Week Herald. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://weekherald.com/2018/02/20/biotime-btx-earns-buy-rating-from-analysts-at-lake-street-capital.html.
BioTime Company Profile
BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.
Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.